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Objectives
We investigated whether differences in cognitive performance between people living with HIV
(PLWH) and comparable HIV-negative people were mediated or moderated by depressive symptoms
and lifestyle factors.
Methods
A cross-sectional study of 637 ‘older’ PLWH aged ≥ 50 years, 340 ‘younger’ PLWH aged
< 50 years and 276 demographically matched HIV-negative controls aged ≥ 50 years enrolled in
the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) study was performed.
Cognitive function was assessed using a computerized battery (CogState). Scores were standardized
into Z-scores [mean = 0; standard deviation (SD) = 1] and averaged to obtain a global Z-score.
Depressive symptoms were evaluated via the Patient Health Questionnaire (PHQ-9). Differences
between the three groups and the effects of depression, sociodemographic factors and lifestyle
factors on cognitive performance were evaluated using median regression. All analyses accounted
for age, gender, ethnicity and level of education.
Results
After adjustment for sociodemographic factors, older and younger PLWH had poorer overall
cognitive scores than older HIV-negative controls (P < 0.001 and P = 0.006, respectively). Moderate
or severe depressive symptoms were more prevalent in both older (27%; P < 0.001) and younger
(21%; P < 0.001) PLWH compared with controls (8%). Depressive symptoms (P < 0.001) and use of
hashish (P = 0.01) were associated with lower cognitive function; alcohol consumption (P = 0.02)
was associated with better cognitive scores. After further adjustment for these factors, the difference
between older PLWH and HIV-negative controls was no longer significant (P = 0.08), while that
between younger PLWH and older HIV-negative controls remained significant (P = 0.01).
Conclusions
Poorer cognitive performances in PLWH compared with HIV-negative individuals were, in part, mediated
by the greater prevalence of depressive symptoms and recreational drug use reported by PLWH.
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Introduction
Despite the widespread use of antiretroviral therapy
(ART), high rates of cognitive impairment, especially in
its milder forms, are reported among people living with
HIV (PLWH). While the burden of cognitive impairment
varies depending on the population studied, the method
used to define cognitive impairment, the uptake of ART
in the population and resulting rates of viral suppression,
the reported prevalence of cognitive impairment ranges
between 17 and 74% [1–3]. We previously reported that
middle-aged PLWH showed poorer overall cognitive per-
formance and were more likely to experience cognitive
impairment even when compared with appropriately
selected HIV-negative controls with similar sociodemo-
graphics and lifestyles [4].
The increased burden of cognitive problems in PLWH
compared with HIV-negative individuals may be par-
tially explained by social factors, mood disorders and
lifestyles, including substance use. Depression, for exam-
ple, is the most common psychiatric condition among
PLWH [5], with a prevalence that can be up to three
times higher than that reported in the general popula-
tion [6,7]. In one meta-analysis based on general popu-
lation studies, depression was reported to be associated
with reduced cognitive functioning in several domains
including psychomotor speed, attention, visual learning
and memory and verbal fluency [8]. Among PLWH, con-
trasting results have been reported regarding the associ-
ation of depressive problems with cognitive function;
while a few studies have reported depressive problems
to be associated with poorer cognitive performance [9]
as well as earlier cognitive decline [10], other studies
have not [11,12].
Lifestyle factors such as alcohol and illicit drug use are
also more prevalent in PLWH than in the general popula-
tion [13–15] and can result in brain injury, neurodegen-
eration and disrupt body processes, especially when used
regularly over a long period of time. These negative
effects may ultimately lead to cognitive disorders [16].
However, depression and lifestyle factors are rarely con-
sidered when comparing the cognitive performance of
PLWH to that of HIV-negative individuals. Whether the
higher rates of depression and substance use seen in
PLWH are responsible, at least in part, for the increased
burden of cognitive disorders remains unclear.
The aims of this study were to compare cognitive per-
formances between PLWH and comparable HIV-negative
controls and to investigate whether differences between
PLWH and HIV-negative controls were either mediated
through or moderated by depressive symptoms and life-
style factors.
Methods
Study design and participants
Cohorts of ‘older’ PLWH aged ≥ 50 years, ‘younger’
PLWH aged < 50 years and demographically matched
‘older’ HIV-negative controls aged ≥ 50 years were
prospectively enrolled in the Pharmacokinetic and Clini-
cal Observations in People Over Fifty (POPPY) study
between April 2013 and January 2016 as detailed else-
where [17]. Inclusion criteria for PLWH were documented
presence of HIV infection, self-defined white or black
African ethnicity, likely route of HIV acquisition via sex-
ual exposure (either by male-to-male exposure if white or
by heterosexual exposure if white or black African) and
the ability to comprehend the study patient information
leaflet. These inclusion criteria ensured that study partici-
pants were representative of the vast majority of PLWH in
the UK and Ireland [18] as has previously been shown [17].
Older HIV-negative controls were frequency matched to
the older HIV-positive group on gender, ethnicity, sexual
orientation and location (in or out of London) and were
recruited from sexual health clinics affiliated with the HIV
clinics, as well as through advertising at community
events, in churches and in targeted publications and from
community groups. The study was approved by the UK
National Research Ethics Service (NRES; Fulham, London;
UK number 12/LO/1409). All participants provided written
informed consent. Analyses presented here are based on
the 637 older PLWH, 340 younger PLWH < 50 years old
and 276 older HIV-negative participants who completed
the assessment of cognitive function as detailed below.
Assessment of cognitive function
Assessment of cognitive function was performed using
the CogState battery [19], a computerized battery of neu-
ropsychological tests that has been used in different clini-
cal settings [20–22], including cohorts of PLWH [23,24].
The battery covered six cognitive domains commonly
reported to be affected by HIV-associated cognitive
impairment, including visual learning, psychomotor func-
tion, visual attention, executive function, verbal learning
and working memory [25] (see Table S1 for details of
individual tests and how they map onto cognitive
domains). Raw test scores were log-transformed or arc-
sine root-transformed as appropriate (and as recom-
mended by the CogState guidelines for analysis;
Table S1) and integrity and quality checks were applied
to ensure that scores were generated from completed and
fully understood tasks for each subject. Individual test
scores not meeting integrity and quality checks were
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excluded from the analysis. Individual test scores were
converted into Z-scores (with a mean of 0 and a standard
deviation of 1) using the means and standard deviations
(SDs) obtained in the whole cohort. A single Z-score was
calculated for each of the six cognitive domains by aver-
aging individual test Z-scores within each domain. A glo-
bal Z-score of overall cognitive function was also
obtained by averaging Z-scores across the six domains.
For all Z-scores, a higher value indicates better cognitive
function. Analyses accounted for the role of obvious
determinants of cognitive performance such as age, gen-
der, ethnicity and level of education as described in the
statistical analysis section.
Lifestyle and depressive symptoms
At enrolment, information was collected on demograph-
ics, socioeconomic status, anthropometrics and lifestyle
factors. In particular, information on past and current
alcohol consumption (including age at which participants
started and stopped consuming alcohol in those who were
abstinent now), smoking habits, use of injected drugs,
and current use of any recreational drugs was collected
via a structured interview with trained staff. Participants
were also asked to specify what recreational drug(s) they
had used over the 6-month period preceding the study
visit, selecting from a predefined list of drugs. Marijuana
and hashish were kept separate; while they originate from
the same plant and contain the same active substance,
they are derived from different parts of the plant and
with different procedures [26]. As, in general, hashish is
stronger than marijuana and their use may reflect differ-
ent lifestyles related to cognitive function, they were
analysed separately.
Severity of depressive symptoms was evaluated using
the Patient Health Questionnaire-9 (PHQ-9) [27]. Scores
range from 0 (no depression) to 27 (severe depression);
participants were categorized as having no (≤ 4), mild (5–
9), moderate (10–14) and severe (≥ 15) depressive symp-
toms using standard cut-offs [27] with the two categories
‘moderately severe’ and ‘severe’ grouped into a single
category (i.e. ‘severe’) because of the small number of
participants falling in each of these two categories.
Statistical analysis
Pairwise group comparisons of sociodemographic charac-
teristics, lifestyle and severity of depressive symptoms
were carried out using v2 and Wilcoxon rank-sum tests
as appropriate. Z-scores were reported as median and
interquartile range (IQR) and pairwise differences between
groups were assessed using the Wilcoxon rank-sum test.
Associations with the global Z-score of cognitive func-
tion were evaluated using multivariable median regres-
sion models to minimize the influence of large outliers.
In all regression models, the covariates age, gender, eth-
nicity and level of education were included as adjusting
factors to mimic the use of normative scores. Appropriate
normative scores were not available for these analyses
given the lack of adequate normative CogState data for
older individuals and the lack of a control group for the
younger PLWH. All regression models included core
covariates such as age, gender, ethnicity and level of
education. Associations with the global Z-score were then
initially assessed using a series of models that included
these core covariates as well as each factor (i.e. depressive
symptoms and sociodemographic and lifestyle factors)
one at a time (step 1). Subsequently, all factors demon-
strating a significant association (at the 5% significance
level) were simultaneously included in a single model,
together with the core covariates (step 2). Only those fac-
tors that remained significantly associated with the out-
come in this model were retained in the next model
which also included the core covariates (step 3). Finally,
HIV status/group was added to this model to evaluate
whether differences between groups appeared to be medi-
ated by these factors (step 4). We also evaluated interac-
tions between HIV status/group and factors in this final
model, to test whether the associations between these fac-
tors and the global Z-score differed across the three study
groups (i.e. whether the associations between lifestyle
factors and cognitive function were modified by HIV sta-
tus/group). In order to assess the clinical relevance of dif-
ferences in overall cognitive scores, we classified as
cognitively impaired participants with a global Z-score
< 0.5, after adjustment for core covariates.
Results
Participant characteristics
Demographic, lifestyle and HIV-related characteristics of
the 637 older PLWH, 340 younger PLWH and 276 older
HIV-negative participants are summarized in Table 1.
Older and younger PLWH had been diagnosed with HIV
infection for a median (IQR) of 16.0 (10.1, 22.4) and 9.6
(5.4, 15.2) years, respectively. The median (IQR) CD4
T-cell count was 620 (470, 799) and 654 (490, 833) cells/
lL, respectively, and 92.3 and 85.8% had a suppressed
viral load (< 50 HIV-1 RNA copies/mL), respectively.
The two older groups of PLWH and HIV-negative con-
trols were comparable in terms of age [median age was 56
(interquartile range (IQR) 53, 62) and 58 (IQR 53, 63) years
in older PLWH and HIV-negative participants, respectively;
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P = 0.11], ethnicity (P = 0.13) and country of birth
(P = 0.41). Older PLWH were more likely to be male (88.5
versus 65.2%, respectively; P < 0.001), men who have sex
with men (MSM) (79.9 versus 50.0%, respectively; P < 0.001)
and single (47.3 versus 29.6%, respectively; P < 0.001) and
to have reported recreational drug use in the 6 months pre-
ceding study entry (25.8 versus 15.2%, respectively;
P < 0.001) compared with older HIV-negative controls. In
Table 1 Demographic, lifestyle and HIV-related characteristics of people living with HIV (PLWH) ≥ 50 and < 50 years old, and HIV-negative
study participants ≥ 50 years old at enrolment
Variable
PLWH ≥ 50 years
(n = 637)
PLWH < 50 years
(n = 340) P1
HIV-negative ≥ 50 years
(n = 276) P2 P3
Gender 0.001 < 0.001 < 0.001
Male 564 (88.5) 275 (80.9) 180 (65.2)
Female 73 (11.5) 65 (19.1) 96 (34.8)
Age (years) 56 (53, 62) 43 (37, 47) < 0.001 58 (53, 63) 0.11 < 0.001
Ethnicity 0.002 0.13 0.001
Black African 77 (12.1) 66 (19.4) 24 (8.7)
White 560 (87.9) 274 (80.6) 252 (91.3)
Country of birth < 0.001 0.41 < 0.001
UK/Ireland 446 (70.0) 173 (50.9) 207 (75.0)
Rest of Europe 41 (6.4) 54 (15.9) 15 (5.4)
Africa 111 (17.4) 78 (22.9) 37 (13.4)
Rest of the world 39 (6.1) 35 (10.3) 17 (6.2)
Sexual orientation 0.007 < 0.001 < 0.001
MSM/homosexual 509 (79.9) 246 (72.4) 138 (50.0)
Heterosexual 128 (20.1) 94 (27.6) 138 (50.0)
Education 0.34 0.05 0.12
No qualifications 63 (9.9) 22 (6.5) 14 (5.1)
O levels/GCSEs 93 (14.6) 54 (15.9) 37 (13.4)
A levels 82 (12.9) 52 (15.3) 35 (12.7)
University 258 (40.5) 142 (41.8) 109 (39.5)
Other/not known 141 (22.1) 70 (20.6) 81 (29.4)
Marital status 0.002 < 0.001 < 0.001
Single 301 (47.3) 174 (51.2) 83 (29.6)
Married/in a relationship 269 (42.2) 154 (45.3) 149 (54.0)
Divorced 43 (7.1) 7 (2.1) 32 (11.6)
Widow/widower 22 (3.5) 5 (1.5) 12 (4.4)
Alcohol consumption 0.35 0.007 0.08
Never consumed 46 (7.2) 29 (8.5) 14 (5.1)
Previously consumed only 84 (13.2) 35 (10.3) 19 (6.9)
Currently consuming 507 (79.6) 276 (81.2) 243 (88.0)
If current/previous consumption
Years drinking 39 (35, 45) 25 (19, 30) < 0.001 41 (36, 46) 0.04 < 0.001
Units/week 8 (3, 18) 6 (2, 16) 0.08 10 (3, 20) 0.35 0.02
Smoking status 0.002 0.03 < 0.001
Never smoked 247 (39.0) 145 (42.9) 123 (44.7)
Ex-smoker 242 (38.2) 93 (27.5) 110 (40.0)
Current smoker 145 (22.9) 100 (29.6) 42 (15.3)
If current/ex-smoker
Years smoked 33 (20, 39) 21 (14, 27) < 0.001 29 (16, 38) 0.009 < 0.001
Cigarettes per day 11 (5, 20) 10 (5, 15) 0.02 10 (3, 20) 0.32 0.76
Ever injected drugs 59 (9.3) 46 (13.6) 0.04 6 (2.2) < 0.001 < 0.001
Recreational drugs 164 (25.8) 116 (34.1) 0.006 42 (15.2) < 0.001 < 0.001
Depressive symptoms 0.36 < 0.001 < 0.001
None 303 (51.8) 172 (54.8) 214 (82.0)
Mild 126 (21.5) 75 (23.9) 27 (10.3)
Moderate 84 (14.4) 36 (11.5) 12 (4.6)
Severe 72 (12.3) 31 (9.9) 8 (3.1)
Duration of HIV infection (years) 16.0 (10.1, 22.4) 9.6 (5.4, 15.2) < 0.001 NA NA NA
CD4 T-cell count (cells/lL) 620 (470, 799) 654 (490, 833) 0.20 NA NA NA
CD4 T-cell % 31 (24, 38) 33 (26, 39) 0.01 NA NA NA
Nadir CD4 count (cells/lL) 180 (85, 270) 258 (158, 384) < 0.001 NA NA NA
On ART 631 (99.1) 325 (95.6) < 0.001 NA NA NA
HIV RNA < 50 copies/mL 586 (92.3) 290 (85.8) 0.001 NA NA NA
Values are n (%) or median (interquartile range). P1: test comparing PLWH ≥ 50 years and PLWH < 50 years; P2: test comparing PLWH ≥ 50 years and
HIV-negative individuals ≥ 50 years; P3: test comparing PLWH < 50 years and HIV-negative individuals ≥ 50 years.ART, antiretroviral therapy; GCSE,
General Certificate of Secondary Education; MSM, men who have sex with men; NA, not applicable.
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particular, older PLWH were more likely to have reported
use of marijuana (14.3 versus 4.7%, respectively; P <
0.001), amphetamine (7.4 versus 4.0%, respectively; P =
0.05) and cocaine (6.9 versus 3.3%, respectively; P = 0.03),
compared with older HIV-negative controls (Table S2).
Current smoking was more common in PLWH (P = 0.03),
while current alcohol consumption was more prevalent in
HIV-negative controls than PLWH (P = 0.007).
Compared with older PLWH, younger PLWH were less
likely to be male (80.9%; P = 0.001) and MSM (72.4%;
P = 0.007) and more likely to be single (51.2%;
P = 0.002). There were no differences in terms of educa-
tional attainment (P = 0.34) or alcohol consumption
(P = 0.35); however, current smoking (22.9% in PLWH
≥ 50 years versus 29.6% in PLWH < 50 years;
P = 0.002), use of any recreational drug (25.8 versus
34.1%, respectively; P = 0.006) and use of most individ-
ual drugs (Table S2) were more frequent in younger
PLWH compared with older PLWH.
Depressive symptoms
Fifty-two older PLWH, 26 younger PLWH and 15 older HIV-
negative participants did not complete the questionnaire on
depressive symptoms and were excluded from analyses that
incorporated this measure. Of note, a sensitivity analysis
showed that those who did not complete the questionnaire
on depressive symptoms were similar to those who did with
regard to most sociodemographic and lifestyle characteris-
tics. However, black Africans and those with lower educa-
tional attainment were less likely to have completed the
questionnaire compared with those of white ethnicity (87.4
versus 93.4%, respectively; P = 0.006) and those with higher
qualifications (88.9 versus 96.2% in those with O levels/
GCSEs, 95.3% in those with A levels and 95.9% in those with
a university degree; P = 0.03), respectively.
The median (IQR) PHQ-9 score was 4 (1, 10), 4 (1, 8)
and 1 (0, 3) in older PLWH, younger PLWH and older
HIV-negative participants, respectively. Scores were sig-
nificantly higher in both older and younger PLWH, com-
pared with older HIV-negative controls (both P < 0.001)
but did not differ significantly between older PLWH and
younger PLWH (P = 0.23). Similarly, moderate and severe
depressive symptoms were more prevalent in the two
groups of PLWH compared with the older HIV-negative
group (both P < 0.001), but there were no differences
between older and younger PLWH (P = 0.36; Table 1).
Domain and global Z-scores
After adjustment for age, gender, ethnicity and level of
education, older PLWH had poorer cognitive scores
overall (P < 0.001) and in the psychomotor (P = 0.008),
visual attention (P = 0.01), executive function (P = 0.04)
and verbal learning (P = 0.007) domains compared with
older HIV-negative participants (Fig. 1 and Table S3).
After adjustment, younger PLWH had poorer cognitive
scores overall (P = 0.006) and in the visual attention
(P = 0.006), verbal learning (P = 0.05) and working
memory (P = 0.02) domains than older HIV-negative
controls. While older PLWH had poorer visual learning
scores compared with younger PLWH (P = 0.03), there
were no differences in overall cognitive scores (P = 0.82)
and scores for other domains.
One hundred and thirteen (17.7%) older PLWH, 54
(15.9%) younger PLWH and 34 (12.3%) older HIV-nega-
tive controls were classified as cognitively impaired.
While this proportion was greater in older PLWH com-
pared with HIV-negative controls (P = 0.04), there were
no differences between younger PLWH and older controls
(P = 0.21) and between older and younger PLWH
(P = 0.46).
Associations between global cognitive function and
lifestyle
We evaluated associations between lifestyle factors and
the global Z-score in the whole study population. From
univariate analyses (model 1), marital status (P = 0.04),
alcohol consumption (P = 0.03), years of alcohol con-
sumption (P = 0.02), use of marijuana (P = 0.03) and use
of hashish (P = 0.01) were associated with global cogni-
tive scores, independently of the core covariates (age,
gender, ethnicity and level of education; Table 2). Sever-
ity of depressive symptoms was significantly associated
with global Z-scores, with better scores for participants
without symptoms (P < 0.001) or only reporting mild
symptoms (P = 0.003) compared with those reporting
severe symptoms.
When considered simultaneously (model 2), only
depressive symptoms (P < 0.001), previous alcohol con-
sumption (P = 0.04) and use of hashish (P = 0.03)
showed associations that were independent of the other
factors. In particular, previous and current alcohol con-
sumption were both associated with better global Z-
scores compared with no consumption (P = 0.007 and
P = 0.006, respectively) with no differences between pre-
vious and current consumption (P = 0.55), while use of
hashish was associated with poorer global cognitive
scores (P = 0.01). Associations remained similar after
excluding the factors that were not significantly associ-
ated (model 3), with use of hashish and more severe
depressive symptoms being associated with poorer cogni-
tive scores.
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Mediation/moderation effect of lifestyle and
depressive symptoms
In model 4, depressive symptoms, alcohol consumption
and use of hashish were still significantly associated with
the global Z-score independently of each other and of
HIV status/group. After the inclusion of these factors, the
adjusted difference between the two older groups was
attenuated and was no longer significant (P = 0.08),
while that between younger PLWH and older HIV-nega-
tive controls remained similar (P = 0.01). Moreover, the
adjusted difference (95% confidence interval) between
older and younger PLWH remained not significant [0.08
(0.02, 0.18); P = 0.11].
There were no significant interactions between HIV
status/group and either alcohol consumption (P = 0.45)
or use of hashish (P = 0.19). The interaction between
HIV status and depressive symptoms was, however, sig-
nificant (P = 0.03), suggesting that the association
between depressive symptoms and cognitive function is
modified by HIV status/group. Figure 2 depicts the esti-
mated differences in the median global Z-score associ-
ated with depressive symptoms and HIV status/group
when compared with the median scores in older
HIV-negative individuals with no depressive symptoms.
Cognitive scores in those reporting greater depressive
symptoms (especially in those with severe depressive
symptoms) were poorer in both older and younger PLWH
compared with scores observed in older HIV-negative
participants. However, this interaction was no longer sig-
nificant once analyses were restricted to participants
without depressive symptoms or with mild or moderate
symptoms (P = 0.16).
Discussion
These data suggest that poorer cognitive function seen in
older PLWH, when compared with similarly aged HIV-
negative individuals with similar lifestyles, are, in part,
mediated by the greater prevalence of depressive symp-
toms reported by PLWH. Moreover, differences were also
driven by the use of substances such as alcohol and
recreational drugs.
When compared with HIV-negative individuals with
similar lifestyle and sexual risk-taking behaviours, and
when accounting for sociodemographic factors only,
PLWH exhibit overall poorer cognitive functioning in sev-
eral domains such as visual attention, working memory
and verbal learning. Similar results have been previously
reported [4,28] and seem to indicate HIV infection as the
Fig. 1 Domain and global Z-scores in people living with HIV (PLWH) ≥ 50 years old, PLWH < 50 years old and HIV-negative participants ≥ 50
years old adjusted for age, gender, ethnicity and level of education.
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Table 2 Estimated regression coefficients (with 95% confidence intervals) obtained from multivariable median regression models to
investigate associations between the global Z-score of cognitive function and sociodemographics, lifestyle factors, depressive symptoms and
HIV status/group
Step 1 Step 2 Step 3 Step 4
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
HIV status/group (ref. HIV-negative individuals ≥ 50 years)
PLWH
≥ 50 years
0.14 (0.22, 0.06) < 0.001 0.08 (0.16, 0.01) 0.08
PLWH
< 50 years
0.17 (0.28, 0.05) 0.006 0.15 (0.27, 0.03) 0.01
Sexuality (ref. MSM)
Heterosexual 0.01 (0.12, 0.11) 0.94
Marital status (ref. married/in a relationship)
Single 0.09 (0.16, 0.02) 0.009 0.05 (0.11, 0.02) 0.15
Divorced 0.07 (0.20, 0.07) 0.31 0.002 (0.13, 0.13) 0.98
Widow/widower 0.17 (0.36, 0.03) 0.09 0.09 (0.28, 0.95) 0.33
BMI (per 5 kg/m2
increase)
0.03 (0.07, 0.01) 0.12
Depressive symptoms (ref. none)
Mild 0.08 (0.17, 0.001) 0.05 0.09 (0.17, 0.01) 0.03 0.09 (0.17, 0.01) 0.02 0.09 (0.17, 0.01) 0.03
Moderate 0.17 (0.28, 0.07) 0.001 0.20 (0.30, 0.10) < 0.001 0.17 (0.27, 0.07) 0.001 0.19 (0.29, 0.09) < 0.001
Severe 0.28 (0.39, 0.17) < 0.001 0.31 (0.42, 0.20) < 0.001 0.28 (0.39, 0.17) < 0.001 0.26 (0.37, 0.15) < 0.001
Alcohol consumption (ref. never consumed)
Previously
consumed only
0.18 (0.03, 0.33) 0.02 0.20 (0.01, 0.39) 0.04 0.20 (0.05, 0.358) 0.01 0.25 (0.10, 0.40) 0.001
Currently
consuming
0.17 (0.05, 0.30) 0.008 0.12 (0.09, 0.33) 0.26 0.17 (0.04, 0.30) 0.01 0.18 (0.05, 0.30) 0.006
Years of drinking
(per 5 years)




Ex-smoker 0.04 (0.04, 0.13) 0.31
Never smoked 0.02 (0.07, 0.10) 0.67
Years of smoking
(per 5 years)
0.01 (0.01, 0.02) 0.50
Ever injected drugs
(yes versus no)





0.04 (0.11, 0.03) 0.29
Marijuana
(yes versus No)
0.13 (0.22, 0.05) 0.005 0.04 (0.06, 0.14) 0.43
Amphetamine
(yes versus no)
0.03 (0.14, 0.08) 0.58
Cocaine
(yes versus no)
0.08 (0.19, 0.04) 0.21
GBL/GHB
(yes versus no)
0.02 (0.16, 0.12) 0.79
Hashish
(yes versus no)
0.25 (0.44, 0.05) 0.01 0.21 (0.43, 0.002) 0.05 0.27 (0.47, 0.06) 0.01 0.29 (0.49, 0.09) 0.005
Inhalants
(yes versus no)
0.08 (0.07, 0.22) 0.29
Ketamine
(yes versus no)
0.01 (0.10, 0.11) 0.93
LSD (yes
versus no)
0.14 (0.45, 0.18) 0.39
MDMA
(yes versus no)
0.05 (0.19, 0.09) 0.46
Crystal meth
(yes versus no)
0.03 (0.15, 0.08) 0.58
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main culprit. However, consistent with previous studies,
we also found that PLWH reported a greater burden of
depressive symptoms [6] which are also associated with
reduced overall cognitive scores [9,29]. Adding to these
studies, which focused on cohorts of PLWH with lower
proportions of ART use and viral suppression, and lower
CD4 T-cell counts than would be typical in the current era
in resource-rich countries, our findings confirm such an
association in ART-treated PLWH with stable viral
suppression. More importantly, the difference in overall
cognitive scores between HIV-negative individuals and
similarly aged PLWH was attenuated when these depressive
symptoms were taken into account. This finding suggests
that depression may act as confounding factor of the asso-
ciation between HIV infection and cognitive function and,
therefore, previous reports of PLWH with poorer cognitive
functioning than HIV-negative controls, not accounting
for depression, may have overestimated the independent
effect of HIV. Of note, however, the attenuation of differ-
ences in overall cognitive scores between younger PLWH
and older HIV-negative controls, consequent to account-
ing for depressive symptoms, was less evident, possibly
because of lower rates of moderate/severe depressive
symptoms seen in younger PLWH compared with those
seen in older PLWH.
Differences in cognitive scores between PLWH and older
HIV-negative controls appeared at least marginally statisti-
cally significant; however, the size of the association with
HIV infection itself (effect sizes of 0.14 and 0.17 for
older and younger PLWH, respectively) appeared to be
moderate, broadly equating to the association seen
between mild/moderate depression and the global Z-score
Table 2 (Continued )
Step 1 Step 2 Step 3 Step 4
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
Difference (95% CI)
in the median Z-score P
Mephedrone
(yes versus no)
0.05 (0.45, 0.36) 0.83
Step 1: core covariates (age, gender, ethnicity and education) + one factor at a time; step 2: core covariates + significant factors in the models in step
1 (P < 0.05) excluding HIV status/group; step 3: core covariates + significant factors in the model in step 2 (P < 0.05); step 4: core covariates + sig-
nificant factors in the model in step 3 (P < 0.05) + HIV status/group.BMI, body mass index; CI, confidence interval; MSM, men who have sex with
men; PLWH, people living with HIV; GBL, gamma butyrolactone; GHB, gamma hydroxybutyrate; LSD, Lysergic acid diethylamide; MDMA, 3,4-methyle-
nedioxy-methamphetamine.
Fig. 2 Difference (95% confidence interval) in the median global Z-score by severity of depressive symptoms and group. The median
(interquartile range) global Z-score for HIV-negative controls ≥ 50 years old with no depressive symptoms was 0.20 (0.15, 0.46).
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(effect sizes of 0.08 and 0.17, respectively). While this
is likely to be attributable to the beneficial effects of ART
on suppression of HIV replication, the differences in overall
scores and in rates of cognitive impairment reported here
are smaller than those reported in other studies [30,31].
This may reflect the more appropriate selection of an HIV-
negative control group with similar lifestyles to the PLWH.
Of note, our findings are consistent with those from the co-
morbidity in relation to HIV/AIDS study [32,33] in which
baseline differences between PLWH and comparable con-
trols did not increase with longer follow-up.
The link between HIV infection and depression is likely
to be bi-directional and multifactorial, involving both
biological and psychosocial/social factors [7]. Among
others, the impact of being diagnosed with HIV infection,
associated stigma, social isolation and discrimination
may all lead to depressive disorders among PLWH. In
turn, depression may cause poor concentration and lack
of interest in and apathy towards cognitive testing and
therefore confound the association between HIV infection
and cognitive function. However, emerging evidence sug-
gests that HIV replication in the central nervous system
(CNS) may cause depression through alterations of brain
structure [34,35], somatostatin dysregulation [36] and
increased concentrations of inflammatory cytokines [37].
As depression is also associated with chronic, low-grade
inflammation and cell-mediated immune activation
[38,39], cognitive problems and depression may represent
a unique manifestation of the same underlying pathologi-
cal process as a result of the direct and indirect effects of
HIV replication in the CNS. More research is justified to
investigate the consequences of CNS HIV replication and
blood–brain barrier dysfunction for mood disorders and
cognitive function.
Our results suggest that current or previous alcohol
consumption and recreational use of hashish (but not
marijuana) may be important determinants of overall
cognitive function, independent of depressive symptoms,
and can attenuate differences in cognitive scores between
PLWH and HIV-negative individuals. We report better
cognitive scores among past or current drinkers compared
with nondrinkers in a cohort with overall moderate con-
sumption [the median (IQR) self-reported alcohol con-
sumption was 8 (2, 18) units per week, below the 14
units per week recommended by UK guidelines [40]]. In
the general population, most studies have also shown that
moderate drinkers tend to perform better on cognitive
tests than nondrinkers [41,42], while a few studies have
not [43]. An association between moderate alcohol intake
and better cognitive function may reflect good physical
and mental health and/or social position [44], as well as
a decreased risk of cardiovascular disease [45], which has
been shown to share common risk factors with cognitive
problems even in PLWH [46]. However, current nondrink-
ing status may reflect previous hazardous over-consump-
tion which may be associated with brain injury (i.e.
reverse causation).
Long-term use of recreational drugs such as hashish has
been linked with poorer cognitive performances in other
settings [47], including cohorts of PLWH [1,48]. Interest-
ingly, marijuana use was not related to overall cognitive
function after accounting for depressive symptoms, alcohol
consumption and use of hashish. As marijuana and hashish
contain the same active substance, this is likely to reflect
differences in frequency, quantity and age of onset of use
and other unmeasured lifestyle factors (e.g. use of other
drugs or sexual risk-taking behaviours) between people
reporting use of only one of the drugs and those reporting
use of both drugs (19 of the 30 participants reporting use of
hashish also reported use of marijuana). Moreover, the self-
reported nature of information regarding substance use
may have introduced a bias as a consequence of the subjec-
tive interpretation of the different types of recreational
drugs listed in the structured questionnaire. PLWH were
more likely to report recreational use of hashish in the
6 months preceding the study visit, compared with older
HIV-negative individuals (2.0, 4.1 and 1.1% in older PLWH,
younger PLWH and older HIV-negative individuals, respec-
tively). When we accounted for both the use of hashish and
alcohol consumption, as well as depressive symptoms, the
initial differences in cognitive scores between older PLWH
and similarly aged HIV-negative individuals were largely
attenuated. This suggests that, together with depression,
these important confounding factors should be considered
when assessing the cognitive performances of PLWH, espe-
cially when the comparison is made with individuals from
the general population, where consumption of recreational
drugs is less prevalent. Moreover, these findings further
highlight the importance of early clinical management of
depression and of interventions targeting modifiable risk
factors as well as their potential beneficial effects in the
short term on cognitive performances among PLWH.
Interestingly, use of other substances, including
cocaine, amphetamine and crystal meth, did not seem to
be associated with overall cognition. While this may
reflect a lack of statistical power (numbers of participants
reporting each individual drug may not be sufficient to
detect significant associations), detailed information on
quantity and frequency of use would be required to shed
further light on whether recreational drug use is also
associated with cognitive function, independently of
other lifestyle factors and depressive symptoms.
While raw cognitive scores were overall poorer in older
PLWH compared with younger PLWH (data not shown),
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there were no substantial differences after accounting for
age and sociodemographic factors, nor after further adjust-
ment for depressive symptoms, alcohol consumption and
recreational drug use. Therefore, the difference initially
seen between older and younger PLWH can be mainly
attributed to the effects of age and other factors potentially
associated with age (e.g. level of education). Inclusion of a
group of younger HIV-negative individuals would be ideal
to investigate whether the effects of age are stronger in
PLWH than those expected in HIV-negative individuals.
Our study has limitations. The cross-sectional nature of
our analysis does not allow the assessment of causal rela-
tionships and the direction of the associations, which is
likely to be bi-directional between cognitive perfor-
mances and depression, alcohol consumption and recre-
ational drug use. Although great effort was made to
include a comparable HIV-negative control group, differ-
ences in some demographic and lifestyle factors were pre-
sent. Also, the lack of a younger (i.e. < 50 years old)
HIV-negative control group may have resulted in an
underestimation of cognitive function of younger PLWH.
These issues were addressed by adjusting all statistical
analyses for age and other demographic factors; however,
it is not possible to rule out the possibility that unmea-
sured confounders may have affected our results. Another
limitation results from the self-reported nature of infor-
mation provided by study participants, which includes
depressive symptoms, smoking, alcohol consumption and
recreational drug use. These data were self-reported for
practical reasons, but clearly such data may be subject to
exaggerations of symptoms or social desirability bias.
In conclusion, our results suggest that comparisons of
cognitive performances between PLWH and HIV-negative
controls should take into account depressive symptoms
and lifestyle factors. Both depression and cognitive prob-
lems remain prevalent in PLWH, even among those
receiving effective ART, with significant implications for
quality of life. It is therefore important to further eluci-
date the pathogenesis of HIV in the brain and the effect
of the interaction between HIV infection and mood disor-
ders on the development of cognitive dysfunction in
PLWH.
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